fedratinib 100 MG Oral Capsule

RxCUI: 2197495
RxNorm name: fedratinib 100 MG Oral Capsule
Display name: fedratinib 100 MG Oral Capsule
Full name: fedratinib 100 MG Oral Capsule
Term type: PSN
Status: DailyMed mapping
Updated: 2026-06-04 23:39:27

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
Inrebic	FEDRATINIB HYDROCHLORIDE	Celgene Corporation	f0f55a2a-4e0c-4cba-8571-03e1424486d7	2026-07-20	Boxed warning, Warnings, Adverse reactions	Exact identifier rxcui: 2197495

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set ID	RxNorm string	TTY	SPL version	Label	Effective
f0f55a2a-4e0c-4cba-8571-03e1424486d7	fedratinib 100 MG Oral Capsule	PSN	11	These highlights do not include all the information needed to use INREBIC safely and effectively. See full prescribing information for INREBIC. INREBIC ® (fedratinib) capsules, for oral use Initial U.S. Approval: 2019	20260318
f0f55a2a-4e0c-4cba-8571-03e1424486d7	fedratinib (as fedratinib dihydrochloride 117.3 MG) 100 MG Oral Capsule	SY	11	These highlights do not include all the information needed to use INREBIC safely and effectively. See full prescribing information for INREBIC. INREBIC ® (fedratinib) capsules, for oral use Initial U.S. Approval: 2019	20260318
f0f55a2a-4e0c-4cba-8571-03e1424486d7	fedratinib 100 MG Oral Capsule	SCD	11	These highlights do not include all the information needed to use INREBIC safely and effectively. See full prescribing information for INREBIC. INREBIC ® (fedratinib) capsules, for oral use Initial U.S. Approval: 2019	20260318